A detailed history of Hhlr Advisors, Ltd. transactions in Cytek Biosciences, Inc. stock. As of the latest transaction made, Hhlr Advisors, Ltd. holds 6,657,030 shares of CTKB stock, worth $34.6 Million. This represents 0.96% of its overall portfolio holdings.

Number of Shares
6,657,030
Previous 6,657,030 -0.0%
Holding current value
$34.6 Million
Previous $44.7 Million 16.84%
% of portfolio
0.96%
Previous 0.99%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Aug 14, 2023

SELL
$6.69 - $11.99 $7 Million - $12.5 Million
-1,046,484 Reduced 13.58%
6,657,030 $56.9 Million
Q1 2023

May 15, 2023

SELL
$8.44 - $13.47 $8.28 Million - $13.2 Million
-981,016 Reduced 11.3%
7,703,514 $70.8 Million
Q4 2022

Feb 14, 2023

SELL
$9.71 - $15.86 $703,975 - $1.15 Million
-72,500 Reduced 0.83%
8,684,530 $88.7 Million
Q3 2021

Nov 15, 2021

BUY
$17.52 - $27.93 $153 Million - $245 Million
8,757,030 New
8,757,030 $187 Million

Others Institutions Holding CTKB

About Cytek Biosciences, Inc.


  • Ticker CTKB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Devices
  • Shares Outstandng 134,627,008
  • Market Cap $700M
  • Description
  • Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers ...
More about CTKB
Track This Portfolio

Track Hhlr Advisors, Ltd. Portfolio

Follow Hhlr Advisors, Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Hhlr Advisors, Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Hhlr Advisors, Ltd. with notifications on news.